Zenas BioPharma, Inc. (ZBIO)
| Market Cap | 2.05B +211.7% |
| Revenue (ttm) | n/a +100.0% |
| Net Income | -425.15M |
| EPS | -8.82 |
| Shares Out | 63.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 263,866 |
| Open | 32.85 |
| Previous Close | 32.17 |
| Day's Range | 31.65 - 33.08 |
| 52-Week Range | 13.50 - 44.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 43.50 (+34.14%) |
| Earnings Date | Aug 13, 2026 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an ext... [Read more]
Financial Performance
In 2025, Zenas BioPharma's revenue was $10.00 million, an increase of 100.00% compared to the previous year's $5.00 million. Losses were -$377.74 million, 140.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price target is $43.5, which is an increase of 34.14% from the latest price.
News
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit showcased a strong pipeline with obexelimab nearing commercialization for IgG4-RD, supported by positive phase III data and strong market interest. Orelabrutinib and other neuro candidates are advancing in late-stage trials, with several key data readouts and regulatory milestones expected in the next year.
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to bei...
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucoc...
Zenas BioPharma Slides: Corporate presentation
Zenas BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Zenas BioPharma submits BLA to FDA for obexelimab
Zenas BioPharma (ZBIO) announced the submission of its biologics license application, or BLA, to the FDA for obexelimab in Immunoglobulin G4-Related Disease. IgG4-RD is a debilitating chronic fibro-in...
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
- BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBI...
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT -
Zenas BioPharma price target raised to $22 from $21 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Zenas BioPharma (ZBIO) to $22 from $21 and keeps an Equal Weight rating on the shares.
Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma
Citi analyst Yigal Nochomovitz added an “upside 30-day catalyst watch” on shares of Zenas BioPharma (ZBIO) while keeping a Buy rating on the name with a $41 price target The…
Zenas BioPharma Slides: Corporate presentation
Zenas BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021
Zenas BioPharma (ZBIO) announced that the first subject has been dosed in the Phase 1 trial of ZB021, a novel potentially best-in-class oral IL-17AA/AF inhibitor. The Phase 1 trial is…
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis -
Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year
Reports Q1 revenue $0 vs. $10M last year. As of March 31 the Company’s cash, cash equivalents and investments were $718.5M. “This quarter we continued to execute across our portfolio…
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results –
Zenas BioPharma Earnings release: Q1 2026
Zenas BioPharma released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Zenas BioPharma Quarterly report: Q1 2026
Zenas BioPharma has published its Q1 2026 quarterly earnings report on May 13, 2026.
Zenas BioPharma Transcript: AGM 2026
The meeting confirmed a quorum and saw the election of two directors and ratification of the auditor for 2026. No additional shareholder proposals were introduced, and final voting results will be disclosed in a forthcoming Form 8-K.
Zenas BioPharma director buys $1.5M in common stock
In a regulatory filing, Zenas BioPharma (ZBIO) disclosed that its director Hongbo Lu bought 75K shares of common stock on March 31 in a total transaction size of $1.5M. Shares…
Zenas BioPharma 5M share Spot Secondary priced at $20.00
The common stock offering was increased to $100M and priced below last closing price of $22.16. Jefferies, Evercore ISI, Citi and Guggenheim are acting as joint book running managers for…
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to be...
Zenas announces common stock, convertible senior notes offerings
Zenas BioPharma (ZBIO) announced that it has commenced underwritten public offerings of its convertible senior notes due 2032 and shares of its common stock. Jefferies, Evercore ISI, Citigroup and Gug...
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to be...
Zenas BioPharma price target raised to $55 from $45 at Guggenheim
Guggenheim raised the firm’s price target on Zenas BioPharma (ZBIO) to $55 from $45 and keeps a Buy rating on the shares. The firm updated its model to account for…
Zenas BioPharma price target raised to $21 from $19 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Zenas BioPharma (ZBIO) to $21 from $19 and keeps an Equal Weight rating on the shares after the company provided its Q4…